Kronos Bio Inc. news covers the company's historical work as a biopharmaceutical developer of small molecule therapeutics targeting deregulated transcription in cancer and autoimmune disease. Recurring updates include financial results, strategic-alternative reviews, governance changes, expense reductions, and pipeline decisions involving istisociclib and p300 lysine acetyltransferase inhibitor programs.
Company announcements also describe preclinical research for KB-9558 in multiple myeloma and HPV-driven tumors and KB-7898 in autoimmune indications such as Sjögren's disease. Later corporate updates center on material agreements, shareholder matters, capital-structure disclosure, and public-company status changes following the strategic-review process.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.